Impact of chronic and recurrent dermatophytosis on quality of life and psychologic morbidity-a cross-sectional study.
anxiety
chronic and recurrent dermatophytosis
depression
perceived stress
quality of life
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
revised:
08
09
2021
received:
22
07
2021
accepted:
02
12
2021
pubmed:
14
12
2021
medline:
10
8
2022
entrez:
13
12
2021
Statut:
ppublish
Résumé
Chronic and recurrent dermatophytosis is adversely effecting the psychosocial well-being of patients. To assess the impact of chronic and recurrent dermatophytosis on quality of life and psychological well-being of patients. We performed a cross-sectional study on patients of chronic and recurrent dermatophytosis aged >12 years. Clinical diagnosis was done, followed by appropriate investigations when required. The patients were made to fill up the questionnaires on Dermatology Life Quality Index, Hospital Anxiety and Depression Scale, and Perceived Stress Scale in English and local languages. The responses were coded with 4-point Likert scale. Statistical analysis was done using MedCal Data of 123 patients were analyzed. Mean DLQI score was 21.4 ± 5.6 and main domain affected was "symptoms and feelings." CRD had an "extremely large effect" on QoL (DLQI score 21-30) in 55.3% patients. Mean HADS-A(anxiety) score was 10.1 ± 3.6, and mean HADS-D(depression) score of participants was 7.8 ± 3.2. Mean perceived stress scale (PSS) score was 18.8 ± 4.3. Involvement of >1 site was a risk factor for higher DLQI score suggestive of "extremely large impact" on QoL (OR 34.02,95% CI 5.7-203.2,p = 0.0001), higher/worsened HADS-A score (OR 5.4, 95% CI 1.2-22.9, p = 0.02), and higher/worsened PSS score (OR 6.1, 95% CI 1.1-34.1, p = 0.04). Persistent disease >1 year (OR 11.5, 95% CI 1.9-67.8, p = 0.007) and male gender (OR 0.3, 95% CI 0.1-0.8, p = 0.01) were significant risk factors for anxiety while BSA involvement >10% was a significant risk factor for moderate to severe perceived stress(OR 13.9, 95% CI 1.5-130.7, p = 0.02). Chronic and recurrent dermatophytosis requires a multidisciplinary approach involving psychiatrists, to reduce the psychological burden.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic and recurrent dermatophytosis is adversely effecting the psychosocial well-being of patients.
AIMS
OBJECTIVE
To assess the impact of chronic and recurrent dermatophytosis on quality of life and psychological well-being of patients.
METHODS
METHODS
We performed a cross-sectional study on patients of chronic and recurrent dermatophytosis aged >12 years. Clinical diagnosis was done, followed by appropriate investigations when required. The patients were made to fill up the questionnaires on Dermatology Life Quality Index, Hospital Anxiety and Depression Scale, and Perceived Stress Scale in English and local languages. The responses were coded with 4-point Likert scale. Statistical analysis was done using MedCal
RESULTS
RESULTS
Data of 123 patients were analyzed. Mean DLQI score was 21.4 ± 5.6 and main domain affected was "symptoms and feelings." CRD had an "extremely large effect" on QoL (DLQI score 21-30) in 55.3% patients. Mean HADS-A(anxiety) score was 10.1 ± 3.6, and mean HADS-D(depression) score of participants was 7.8 ± 3.2. Mean perceived stress scale (PSS) score was 18.8 ± 4.3. Involvement of >1 site was a risk factor for higher DLQI score suggestive of "extremely large impact" on QoL (OR 34.02,95% CI 5.7-203.2,p = 0.0001), higher/worsened HADS-A score (OR 5.4, 95% CI 1.2-22.9, p = 0.02), and higher/worsened PSS score (OR 6.1, 95% CI 1.1-34.1, p = 0.04). Persistent disease >1 year (OR 11.5, 95% CI 1.9-67.8, p = 0.007) and male gender (OR 0.3, 95% CI 0.1-0.8, p = 0.01) were significant risk factors for anxiety while BSA involvement >10% was a significant risk factor for moderate to severe perceived stress(OR 13.9, 95% CI 1.5-130.7, p = 0.02).
CONCLUSION
CONCLUSIONS
Chronic and recurrent dermatophytosis requires a multidisciplinary approach involving psychiatrists, to reduce the psychological burden.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3586-3592Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Lopes G, Pinto E, Salgueiro L. Natural products: an alternative to conventional therapy for dermatophytosis? Mycopathologia. 2017;182:143-167.
Shenoy MM, Rengasamy M, Dogra S, Kaur T, Asokan N, Sarveswari KN, et al. A multicentric clinical and epidemiological study of chronic and recurrent dermatophytosis in India. Mycoses. 2021. doi: 10.1111/myc.13360. Epub ahead of print.
Verma SB, Panda S, Nenoff P, et al. The unprecedented epidemic-like scenario of dermatophytosis in India: I. Epidemiology, risk factors and clinical features. Indian J Dermatol Venereol Leprol. 2021;87:154-175.
Nenoff P, Verma SB, Vasani R, et al. The current Indian epidemic of superficial dermatophytosis due to Trichophyton mentagrophytes-A molecular study. Mycoses. 2019;62:336-356.
Ebert A, Monod M, Salamin K, et al. Alarming India-wide phenomenon of antifungal resistance in dermatophytes: a multicentre study. Mycoses. 2020;63:717-728.
Gupta MA, Gupta AK. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol. 2003;4:833-842.
Das A, Fatima F, Sil A, Podder I, Jafferany M. Therapeutic management of psychological morbidity and impaired quality of life in patients with persistent dermatophytoses. Dermatol Ther. 2020;33:e14124.
Dogra S, Uprety S. The menace of chronic and recurrent dermatophytosis in India: Is the problem deeper than we perceive? Indian Dermatol Online J. 2016;7:73-76.
Wani RT. Socioeconomic status scales-modified Kuppuswamy and UdaiPareekh's scale updated for 2019. J Family Med Prim Care. 2019;8:1846-1849.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. ClinExp Dermatol. 1994;19:210-216.
Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005;125:659-664.
Snaith RP. The hospital anxiety and depression scale. Health Qual Life Outcomes. 2003;1:29.
Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health SocBehav. 1983;24:386-396.
Narang T, Bhattacharjee R, Singh S, et al. Quality of life and psychological morbidity in patients with superficial cutaneous dermatophytosis. Mycoses. 2019;62:680-685.
Patro N, Panda M, Jena A. The menace of superficial dermatophytosis on the quality of life of patients attending referral hospital in Eastern India: a cross-sectional observational study. Indian Dermatol Online J. 2019;10:262.
Mushtaq S, Faizi N, Amin SS, Adil M, Mohtashim M. Impact on quality of life in patients with dermatophytosis. Australas J Dermatol. 2020;61:e184-e188.
Bashir S, Hassan I, Wani RT. Influence of dermatophytosis on quality of life: a cross sectional study from Kashmir Valley in North India. International Journal of Community Medicine and Public Health. 2020;7:1711.
Das NK, Das S. A study to assess the quality of life (QOL) of patients suffering from tinea corporis attending dermatology OPD of a tertiary care centre of Eastern India. Int J Med Res Rev. 2019;7:490-495.
Nayak PB, Girisha BS, Noronha TM. Correlation between disease severity, family income, and quality of life in psoriasis: a study from south india. Indian Dermatol Online J. 2018;9:165-169.
De A, Godse K, Dhoot D, Sarda A. Real-life experience of efficacy and safety of bilastine in the refractory cases of chronic spontaneous urticaria and its effect on the quality of life of patients. Indian J Dermatol. 2021;66:159-164.
Kota RS, Vora RV, Varma JR, Kota SK, Patel TM, Ganjiwale J. Study on assessment of quality of life and depression in patients of vitiligo. Indian Dermatol Online J. 2019;10:153-157.
Khan MI, Kashif M, Iqbal J, et al. Depression in patients with fungal infection in tertiary care hospital. J Pakistan Assoc Dermatologists. 2019;29:402-408.